Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Tekedereli, Ibrahim, Alpay, S Neslihan, Akar, Ugur, Yuca, Erkan, Ayugo-Rodriguez, Cristian, Han, He-Dong, Sood, Anil K, Lopez-Berestein, Gabriel, Ozpolat, Bulent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028016/
https://www.ncbi.nlm.nih.gov/pubmed/24022053
http://dx.doi.org/10.1038/mtna.2013.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028016/
https://www.ncbi.nlm.nih.gov/pubmed/24022053
http://dx.doi.org/10.1038/mtna.2013.45

Ejemplares similares